首页|达格列净联合螺内酯和美托洛尔治疗心力衰竭的临床效果评价

达格列净联合螺内酯和美托洛尔治疗心力衰竭的临床效果评价

扫码查看
目的 研究达格列净联合螺内酯和美托洛尔治疗心力衰竭(HF)的临床效果。方法 150例心力衰竭患者作为研究对象,采用盲选法分为常规组和研究组,每组75例。常规组选择螺内酯联合美托洛尔治疗,研究组在常规组基础上增加达格列净治疗。对比两组临床疗效,治疗3个月后心功能指标[左室收缩末期容积(LVESV)、左室射血分数(LVEF)、左室舒张末期容积(LVEDV)]和神经内分泌因子[血管紧张素Ⅱ(AngⅡ)、醛固酮(ALD)、N末端B型利钠肽前体(NT-proBNP)],不良反应发生情况。结果 研究组临床总有效率98。67% 显著高于常规组的85。33%(P<0。05)。治疗3个月后,研究组LVESV(70。26±8。19)ml、LVEDV(125。78±18。66)ml显著小于常规组的(78。58±8。94)、(138。44±20。31)ml,LVEF(40。98±5。21)% 显著高于常规组的(32。29±4。22)%(P<0。05)。治疗3个月后,研究组AngⅡ、ALD、NT-proBNP水平分别为(65。93±8。22)pg/ml、(552。78±135。98)pmol/L、(797。62±55。23)pg/ml,显著低于常规组的(82。68±5。81)pg/ml、(842。53±141。56)pmol/L、(886。95±62。54)pg/ml(P<0。05)。研究组不良反应发生率为4。00%,与常规组的2。67% 对比无显著差异(P>0。05)。结论 对心力衰竭患者给予达格列净联合螺内酯和美托洛尔能够增强治疗效果,安全性较好。
Evaluation on clinical effect of dapagliflozin combined with spironolactone and metoprolol in the treatment of heart failure
Objective To explore the clinical effect of dapagliflozin combined with spironolactone and metoprolol in the treatment of heart failure (HF). Methods 150 patients with heart failure were selected as the study subjects,all patients were divided into a conventional group and a study group,each with 75 patients. The conventional group was treated with spironolactone combined with metoprolol,and the study group was treated with dapagliflozin based on the conventional group. Both groups were compared in terms of clinical efficacy,cardiac function indicators[left ventricular end-systolic volume (LVESV),left ventricular ejection fraction (LVEF),left ventricular end-diastolic volume (LVEDV)]and neuroendocrine factors[angiotensin Ⅱ (AngⅡ),aldosterone (ALD),N-terminal pro-B-type natriuretic peptide (NT-proBNP)]after 3 months of treatment,and occurrence of adverse reactions. Results The overall clinical efficacy of 98.67% in the study group was significantly higher than 85.33% in the conventional group (P<0.05). After 3 months of treatment,the study group had LVESV of (70.26±8.19) ml and LVEDV of (125.78±18.66) ml,which were significantly lower than (78.58±8.94) and (138.44±20.31) ml in the conventional group;LVEF of (40.98±5.21)% in the study group was significantly higher than (32.29±4.22)% in the conventional group (P<0.05). After 3 months of treatment,the levels of AngⅡ,ALD and NT-proBNP of the study group were (65.93±8.22) pg/ml,(552.78±135.98) pmol/L and (797.62±55.23) pg/ml,which were significantly lower than (82.68±5.81) pg/ml,(842.53±141.56) pmol/L and (886.95±62.54) pg/ml of the conventional group (P<0.05). The incidence of adverse reactions in the study group was 4.00%,which had no significant difference compared with 2.67% in the conventional group (P>0.05). Conclusion Dapagliflozin combined with spironolactone and meetoprolol can enhance the therapeutic effect of patients with heart failure,and have good safety.

Heart failureDapagliflozinSpironolactoneMetoprololClinical effect

袁园

展开 >

213200 江苏省常州市金坛区中医医院

心力衰竭 达格列净 螺内酯 美托洛尔 临床效果

2024

中国现代药物应用
中国水利电力医学科学技术学会

中国现代药物应用

影响因子:0.862
ISSN:1673-9523
年,卷(期):2024.18(23)